Allergan

Insiders may buy shares of a company because they believe its stock price will move higher and want to profit from this anticipated rise. Sell-offs might provide an opportunity for insiders who have faith in a company to snatch up shares. Below are some stocks that have recently seen insider buying...

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

Quarterly reports of note scheduled for this week include those from Archer Daniels Midland (NYSE: ADM), General Motors (NYSE: GM), MasterCard (NYSE: MA), Procter & Gamble (NYSE: PG) and Time Warner (NYSE: TWX), all of which are expected to post earnings growth, as well as Pfizer (NYSE: PFE)...

Morgan Stanley has published a report on Allergan (NYSE: AGN) after a Botox migraine survey was conducted. In the report Morgan Stanley wrote, "Our AlphaWise survey of 350 neurologists suggests that Botox migraine penetration may be faster than we project, but patient pool may be smaller, yielding...

According to a recent report, Bank of America hosted an expert call on the use of Allergan's (NYSE: AGN) Botox for overactive bladder. The expert on the call was Dr. Victor Nitti, who is a Professor and the Vice Chairman of the Department of Urology at NYU Langone Medical Center. Following Dr....

Bank of America is reiterating its Buy rating and its $90 price target on Allergan (NYSE: AGN) following a survey conducted for the market analyst. In the report, Bank of America writes, “Early read supports Botox potential for migraine We commissioned a survey of 75 neurologists that treat...

Bank of America Merrill Lynch is out with its report today on Allergan (NYSE: AGN), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "We believe that AGN is ideally positioned, with a fully integrated, global, specialty-focused model and strong management team. While...

Allergan Inc. (NYSE: AGN) increased its workforce by 300 to 9,500 in 1Q11 after a +900 increase in 2010, Citi reports. “We assume most of the increase came from ex-US markets where AGN is expanding its operations in both eye care & aesthetics,” Citi writes. “On its 1Q11 call AGN indicated that...

According to J.P. Morgan, after strong 1Q results, they are raising the price target on Allergan (NYSE: AGN) to $83.00 from $80.00 and are maintaining the neutral rating. In the report, J.P. Morgan said, "Allergan reported solid 1Q/11 results (+$0.03 EPS beat despite higher than expected SG&A...

Piper Jaffray has raised the price target on Allergan (NYSE: AGN) from $81 to $91 and maintains its Overweight rating.

JP Morgan has raised the price target on Allergan (NYSE: AGN) from $80 to $83 and maintains its Neutral rating.

Morgan Stanley is out with its report today on Allergan (NYSE: AGN), maintaining Overweight. In a note to clients, Morgan Stanley writes, "Many investors wonder about what is in Allergan's pipeline, so we conducted a deep dive analysis on clinical trial websites to try to uncover public...